Early decision about the indication for novel molecular-targeted drug in differentiated thyroid cancer
| Project/Area Number |
16K19810
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
Kayano Daiki 金沢大学, 附属病院, 助教 (10547152)
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 甲状腺分化癌 / 分子標的薬 / I-131内用療法 / 分化型甲状腺癌 |
|---|
| Outline of Final Research Achievements |
We investigated whether radioiodine-131 (I-131) diagnostic scintigraphy under ricombinant human thyroid-stimulating hormone (rhTSH) was useful or not for the decision about the indication for novel molecular-targeted drug in different thyroid cancer. We proved that I-131 diagnostic scintigraphy under rhTSH before I-131 therapy could be useful for the decision about the indication for novel molecular-targeted drug in patients with differentiated thyroid cancer who have thyroid remnant tissue and metastases.
|
| Academic Significance and Societal Importance of the Research Achievements |
残存甲状腺組織と転移病変を有する甲状腺分化癌患者において、rhTSH使用下診断シンチグラフィを施行することにより、I-131内用療法前にI-131治療抵抗性の患者を検出することが可能であり、早い段階で分子標的薬の導入を決定することが可能であることを示した。本研究成果から、rhTSH使用下診断シンチグラフィを用いることによって、不要なI-131内用療法を減らし早い段階で分子標的薬導入を決定することが可能となり、患者にとって治療効果の面だけでなく時間的、経済的側面においても得られる利益は大きいと考えられる。
|
Report
(4 results)
Research Products
(9 results)
